Drug, bio-affecting and body treating compositions inventions 11/05

20050261165 - Methods of reducing microbial resistance to drugs: The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity...

20050261162 - Pharmaceutical composition for preventing and treating cancer and treating an inflammation: The present invention relates to a pharmaceutical composition preventing cancer and treating cancer and inflammation, which is characterized in that including xanthorrhizol as an active principle. Xanthorrhizol not only inhibits mutagenesis and tumor formation, and enhances the activity of detoxification enzyme of carcinogen, induces apoptosis of cancer cell, and suppresses...

20050261163 - Pharmaceutical products, preparation and uses thereof: A pharmaceutical product comprising at least one therapeutic agent, whereby a unit dose of said therapeutic agent as provided by said pharmaceutical product can be administered to a patient during the passage of said therapeutic agent through the gastrointestinal tract of the patient, wherein said therapeutic agent is characterised as...

20050261164 - Remedy for urinary frequency and urinary incontinence: A composition for treating frequent urination and/or urinary incontinence comprising a compound having an activity to inhibit Na+/H+ exchange transporter or its pharmaceutically acceptable salt as an active ingredient....

20050261161 - Stable crystals of pyrrole compound: The present invention is constituted with crystal of 2-amino-3-cyano-4-methyl-5-(2-fluorophenyl)pyrrole, which show diffraction peaks at diffraction angles (2θ±0.2 degree) of 10.3 degree, 14.3 degree, 15.5 degree, 15.9 degree, 25.1 degree and 25.7 degree in a powder X-ray diffraction spectrum, and also show absorption peaks at wavenumbers (cm−1, ±0.2%) of 3373, 3322,...

20050261166 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides....

20050261167 - Compositions for sleeping disorders: Provided herein is a composition that contains an effective amount of one or more compounds for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder and using the composition....

20050261168 - Novel formulations: Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog....

20050261170 - Folate conjugates and complexes: Disclosed are conjugates and complexes that include a folate receptor ligand and one or more therapeutic molecules, such as onconase or a variant thereof such as rapLR1. The conjugates and complexes may be useful as primary therapeutic agents, which may be administered with additional therapeutic or diagnostic agents. Also disclosed...

20050261169 - Peptide and peptide mimetic derivatives having integrin inhibitor properties iii: and salts thereof as integrin inhibitors for the treatment of diseases, defects and inflammation caused by implants and of osteolytic diseases, such as osteoporosis, thrombosis, cardiac infarction and arteriosclerosis, and for the acceleration and strengthening of the integration process of the implant or of the biocompatible surface into the tissue....

20050261172 - Agents and methods for promoting bone growth: Agents for promoting bone deposition and growth in a mammalian subject. The agents are O-glycosylated and non-glycosylated peptides that are derived from vitamin D binding protein, collectively referred to hereinafter as “DBP” peptides. The DBP peptides are from 3 to 18, preferably from 4 to 14 amino acids in length...

20050261171 - Combination cancer therapy: The present invention relates to novel compositions comprising, (i) at least one of Taxol, Taxotere, bleomycin, carmustine, carboplatin, and doxorubicin; and (ii) MGd, a compound of Formula I. The present invention also relates to and methods of using said compositions to treat Cancer....

20050261173 - Antifungal parenteral products: Parenteral pharmaceutical formulations containing an echinocandin antifungal compound and an aqueous solvent are provided, wherein the formulation includes ethanol, for example about 20% w/v ethanol. The parenteral pharmaceutical formulation may further include one or more additives, such as a stabilizing agent, buffer or tonicity agent. The parenteral pharmaceutical formulations are...

20050261174 - Insecticidal activity of a cyclic peptide: A cyclic peptide isolated from an extract of the bark of a Madagascan plant, having a structure of formula (I), has insecticidal activity....

20050261178 - Co-administration of cg250 and il-2 or ifn-alpha for threating cancer such as renal cell carcinomas: A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method...

20050261181 - Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells: Compositions and methods for the treatment of bone diseases, bone fractures, bone injuries and other bone abnormalities involving the use of Dkk protein, a Wnt antagonist, a Wnt inhibitor, or any other related protein for the stimulation or enhancement of mineralization and for stimulating the renewal of cells. One Dkk...

20050261176 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell...

20050261177 - Compound: This invention relates to new polypeptide compound represented by the following general formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to...

20050261190 - Fas associated factor 1: The present application describes a Fas associated Factor 1 protein and fragment thereof that bind Hsc70/Hsp70, ubiquitinated protein and valosin containing protein....

20050261188 - Genes encoding proteins with pesticidal activity: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding δ-endotoxins having pesticidal activity against insect pests. The invention further provides mutagenized nucleic acids that have been modified to encode pesticidal polypeptides such as endotoxins having improved pesticidal activity and/or altered pest specificity....

20050261184 - Method for treating glaucoma: A method for reducing intraocular pressure and increasing outflow facility from an eye of a subject having glaucoma includes the step of providing in the trabecular meshwork of the eye an amount of caldesmon effective to reduce intraocular pressure and increase outflow facility....

20050261187 - Methods and compositions relating to mek5 and cardiac hypertrophy and dilated cardiomyopathy: The present invention relates to compositions and methods relating to MEK5 and its role in heart disease. This protein has now been identified as a target for therapeutic intervention due to its role molecular events that lead to or contribute to cardiac hypertrophy and/or dilated cardiomyopathy. In particular, inhibition of...

20050261189 - Methods of promoting cardiac cell proliferation: The present invention provides novel methods and compositions for promoting proliferation and/or regeneration....

20050261191 - Ngal for reduction and amelioration of ischemic and nephrotoxic injuries: Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective...

20050261192 - Novel polypeptide and its dna: It is intended to construct a screening method, etc. for searching for compounds which are capable of binding to apolipoprotein A-I and thus promote or inhibit the binding of a cubulin fragment to apolipoprotein A-I, and provide preventives or remedies containing compounds obtained by the above screening method, etc. These...

20050261186 - Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods: The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules....

20050261183 - Pthrp-derived modulators of smooth muscle proliferation: The present invention relates to the use of mutants of parathyroid hormone-related protein, to treat disorders associated with smooth muscle cells, and to inhibit the cellular activation and proliferation thereof. The method can be employed in diverse tissues to effect therapeutic and prophylactic relief for disorders and diseases manifested by...

20050261175 - Scf antibody compositions and methods of using the same: Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also disclosed....

20050261185 - Therapeutic proteins: The present invention relates to a method for the treatment of a medical condition associated with obesity and/or insulin resistance, comprising administering to a subject in need thereof an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2 to 10,...

20050261182 - Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin: Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin....

20050261180 - Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions: Methods for treatment of inflammatory and fibrotic conditions in vivo using UG is disclosed. Methods for treating or preventing inflammatory or fibrotic conditions characterized by a deficiency of endogenous functional UG are also disclosed. Compositions containing UG, optionally containing lung surfactant, and assay procedures for detection of UG-fibronectin complexes, are...

20050261179 - Vasoregulating compounds and methods of their use: Methods and compounds are described for regulating blood pressure in a subject. Specific embodiments are methods for reversing vasodilation of blood vessels, by administering to a subject a therapeutically effective amount peptide AM(11-22). The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock,...

20050261193 - Antimicrobial theta defensins and methods of using same: The present invention relates to an isolated cyclic peptide, theta defensin, having antimicrobial activity, and to theta defensin analogs. A theta defensin can have the amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa1-Xaa6-Xaa4-Xaa4-Xaa1-Xaa1-Xaa6-Xaa4-Xaa5-Xaa1-Xaa3-Xaa7-Xaa5, wherein Xaa1 to Xaa8 are defined; wherein Xaa1 can be linked through a peptide bond to Xaa8; and wherein crosslinks can...

20050261196 - Myosin light chain kinase inhibitors and methods of use: Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use....

20050261195 - Process for preparing lh-rh derivatives: A process for the preparation of LH-RH derivatives, characterized by subjecting a solution of an LH-RH derivative to both treatment with a synthetic methacrylic resin adsorbent and that with a synthetic aromatic resin adsorbent. According to this process, the formation of by-product impurities including racemates of LH-RH derivatives can be...

20050261194 - Use of thymulin-like peptides for making pain-relieving medicines: The present invention relates to the utilization of peptide analogues of thymulin that are inactive relative to the immune system, not comprising zinc and having anti-pain activity, for manufacturing a medicine for the treatment of pain....

20050261197 - Coffee bean extract, method of extraction and composition containing the same: A composition containing genistein, flavionic acid, diadzien, diadzin, and a peptide having the amino acid sequence tyrosine-glycine-serine-arginine-serine, as well as pharmaceutical compositions prepared from such compositions possessing anti-inflammatory activity, and a method for isolating each compound and producing such a composition. A heating, extracting and condensing system that efficiently recovers...

20050261201 - Method of reducing c-reactive protein using growth hormone secretagogues: The present invention relates to a method of reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event...

20050261199 - Pharmaceutical composition comprising a retro-iverso isomer peptide: The present invention provides a pharmaceutical composition comprising a peptide selected from the group consisting of D-Pro D-Tyr D-Val D-Val, D-Pro D-Tyr D-Val, and D-Leu D-Thr D-Val as an active component. The composition of the present invention has great efficacy in lowering serum triglyceride levels....

20050261202 - Sensitization to another anticancer therapy and/or amelioration of a side effect of another anitcancer therapy by treatment with a gst-activated anticancer compound: A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated...

20050261198 - Sulfur-containing proanthocyanidin oligomer compositon and process for producing the same: Provided are: method of producing a sulfur-containing proanthocyanidin oligomer by reducing the molecular weight of proanthocyanidin in plants so that they can be readily absorbed through the intestine of an organism; and a health food composition and a pharmaceutical composition which contain the resultant sulfur-containing proanthocyanidin oligomer as an active...

20050261200 - Tri-peptide hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned...

20050261203 - Azabicyclo-octane inhibitors of iap: X1 and X2 are independently O or S; L is a bond or —C(X3)—, —C(X3)NR12, —C(X3)O— wherein X3 is O or S and R12 is H or R1; R1 is alkyl, a carbocycle, carbocycle-substituted alkyl, a heterocycle or heterocycle-substituted alkyl, wherein each is optionally substituted with halogen, hydroxyl, mercapto, carboxyl,...

20050261204 - Novel use of peptide compounds for treating dyskinesia: The present invention is directed to the use of a class of peptide compounds for treating primary or/and secondary dyskinesias such as tardive dyskinesia....

20050261205 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in...

20050261206 - Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof: while the other represents a lower alkyl group or a halo(lower alkyl) group; and R2 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halo(lower alkyl) group or a halogen atom, or pharmaceutically acceptable salts thereof, which have an inhibitory activity in...

20050261207 - Glucose-based compounds with affinity to p-selectin: The present invention relates to certain glucose-based compounds that have an affinity to P-selectin. Further, the invention relates to the use of these glucose-based compounds for the preparation of pharmaceutical compositions for the treatment of disorders associated with P-selectin, to conjugates, pharmaceutical carriers and drug delivery systems comprising said compounds,...

20050261208 - Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and...

20050261209 - Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein: in which formula R1, R2, R3, R4 independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; each of R5, R6, R7 is a hydroxyl group; no more than 3 of R1, R2, R3, R4 are hydrogen atoms; precursors capable of liberating a substance...

20050261210 - Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders: The invention features methods of treating a inherited or acquired cutaneous or gastrointestinal (GI) disorder caused by or having a symptom caused by a nonsense mutation by local administration of a nonsense suppressor agent (e.g., an aminoglycoside or nucleic acid encoding a suppressor tRNA) to the skin or intraluminal GI...

20050261211 - Process for preparing substituted benzimidazole compounds: The invention relates to new methods of preparing substituted benzimidazole compounds, such as 2-bromo-5,6-dichlorobenzimidazole, which are useful in the preparation of compounds having antiviral activity....

20050261235 - 2' ,5' -oligoadenylate analogs: wherein m is 0 or 1; n is 0 to 2; R1 represents an alkoxy group having from 1 to 6 carbon atoms which may be substituted, an unprotected mercapto group, a mercapto group protected by a nucleic acid synthesis protecting group, or an alkylthio group having from 1 to...

20050261228 - Antisense modulation of interleukin 12 p35 subunit expression: Compounds, compositions and methods are provided for modulating the expression of Interleukin 12 p35 subunit. The compositions comprise chemically modified antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interleukin 12 p35 subunit. Methods of using these compounds for modulation of Interleukin 12 p35 subunit expression and for treatment...

20050261214 - Complexes for transferring substances of interest into a cell: The present invention concerns new polar compounds, complexes and compositions comprising them, wherein said compound comprises: (i) a polar headgroup spacer, (ii) at least one hydrophobic moiety, and (iii) at least one hydrophilic polymer, and wherein said polar headgroup spacer is coupled to said hydrophobic moiety and to said hydrophilic...

20050261221 - Compositions and methods for enhanced delivery of compounds via transfection complexes: The present invention relates to compositions and methods for enhanced delivery of compounds (e.g., drugs, nucleic acids, peptides, etc.) via transfection complexes (e.g., liposomes). In particular, the present invention utilizes agents that synergistically enhance the ability of a transfection complex to deliver a compound to cells or tissue....

20050261229 - Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the...

20050261234 - Gfap-based gene therapy for treatment of retinal diseases: Compositions and methods for reducing neovascularization. Purified nucleic acid constructs and vectors encoding an anti-angiogenic protein operably linked to a GFAP promoter. Vectors can include at least one hypoxia regulated element, enhancer element and silencer element. Gene therapy methods for reducing, delaying or preventing neovascularization based on the nucleic acid...

20050261231 - Hepatocyte growth factor nucleic acid sequence to enhance musculocutaneous flap survival: The present invention relates to the use of growth factors in improving tissue survival. In particular, the invention describes methods for enhancing organ transplant, musculocutaneous flap or skin graft survival by administering a nucleic acid sequence encoding hepatocyte growth factor....

20050261230 - Method for the prophylaxis and/or treatment of medical disorders: The present invention relates generally to a method for the prophylaxis and/or treatment of skin disorders, and in particular proliferative and/or inflammatory skin disorders, and to genetic molecules useful for same. The present invention is particularly directed to genetic molecules capable of modulating growth factor interaction with its receptor on...

20050261226 - Methods and compositions for the treatment of cancer with oligonucleotides directed against egr-1: Oligonuclotides, compositions and methods for modulating the over-expression of EGR-1 in cancer cells. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Egr-1. Methods include using these compounds for modulation of Egr-1 expression in cancer cells in which Egr-1 is over-expressed for the treatment of cancer....

20050261215 - Methods and immune modulatory nucleic acid compositions for preventing and treating disease: This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly...

20050261224 - Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not...

20050261233 - Modulation of glucose-6-phosphatase translocase expression: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders....

20050261216 - Modulation of nanos 1 expression: Compounds, compositions and methods are provided for modulating the expression of Nanos 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Nanos 1. Methods of using these compounds for modulation of Nanos 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Nanos 1...

20050261217 - Modulation of pumilio 1 expression: Compounds, compositions and methods are provided for modulating the expression of Pumilio 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Pumilio 1. Methods of using these compounds for modulation of Pumilio 1 expression and for diagnosis and treatment of diseases and conditions associated with expression of Pumilio 1...

20050261232 - Non-natural ribonuclease conjugates as cytotoxic agents: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such...

20050261227 - Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines: The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof,...

20050261213 - Nucleic acid compositions and methods for use: Polynucleotide compositions encoding a tumor antigen antigenic determinant and optionally including a nucleic acid adjuvant are disclosed. The compositions are useful for prophylaxis or treatment of cancer....

20050261218 - Oligomeric compounds and compositions for use in modulation small non-coding rnas: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment...

20050261222 - Oligoribonucleotides for the treatment of irritative or inflammatory skin symptoms through rna interference: The invention is a double-stranded oligoribonucleotide or a physiologically compatible salt thereof, which is capable of inducing the degradation of mRNA of one of more structures involved in inflammation or irritation of the skin. The invention is also cosmetic or therapeutic compositions comprising one or more such double-stranded oligoribonucleotide and...

20050261225 - Peptides that deliver antisense oligonucleotides which downregulate protein expression in cells: The present invention provides a peptide that can complex with an oligonucleotide, e.g. an antisense oligonucleotide, and deliver it into a cell. The present invention also provides compositions comprising a complex of such a peptide and an oligonucleotide and methods of delivering an oligonucleotide into a cell and of inhibiting...

20050261223 - Rip140 regulation of glucose transport: Inhibition of RIP140 increases glucose transport. Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport (e.g., diabetes), treating obesity, increasing metabolism (e.g., fatty acid metabolism), and increasing brown fat....

20050261219 - Rna interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin...

20050261212 - Rna interference mediated inhibition of nogo and nogo receptor gene expression using short interfering rna: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications associated with Alzheimer's disease. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against NOGO...

20050261220 - Tumor treating combinations, compositions and methods: The invention relates to compositions and methods of use in the treatment of tumors in animals. The invention is particularly concerned with the combination of HIF inhibiting agents, specifically antisense HIF-1, with antiangiogenic agents....

20050261236 - Agonists of a2a adenosine receptors for treatment of diabetic nephropathy: The present invention provides a therapeutic method for treating diabetic kidney disease, e.g., diabetic nephropathy that includes the administration of an effective amount of an A2A adenosine receptor agonist. Optionally, the method includes administration of a type IV PDE inhibitor....

20050261238 - Method for increasing muscle mass and strength through administration of adenosine triphosphate: The present invention is directed to compositions having an effective amount of Adenosine Triphosphate (“ATP”) sufficient to effect intracellular and extracellular concentrations of ATP in a mammal to improve anaerobic exercise capacity by increasing muscle size and/or strength and methods for using the same. Preferably, a gastric acid secretion inhibitory...

20050261237 - Nucleoside phosphonate analogs: The invention is related to phosphorus substituted nucleoside compounds and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20050261239 - Use of atp for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue: The present invention provides the use of ATP for the manufacture of a medicine for exerting a pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: 1°. modulating inflammation by inhibiting the inflammatory response to a strong external insult such as endotoxin (LPS)...

20050261240 - Carrageenan based antimicrobial compositions: Disclosed are compositions for inhibiting transmission of a sexually transmitted infection that contain one or more carrageenans, including lambda carrageenan. Also disclosed are methods for making and using the compositions....

20050261241 - Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses: Dermatan sulfates and/or O-desulfated heparins useful in treating and preventing heparinoid-induced autoimmune responses, in particular heparin-induced thrombocytopenia (HIT) and its associated disease states. The dermatan sulfates comprise repeating disulfated and/or trisulfated disaccharide units of L-iduronic acid and N-acetyl-D-galactosamine. The O-desulfated heparins comprise heparin molecules selectively O-desulfated at the 2-O and/or...

20050261243 - Antiprostaglandins for the treatment of ocular pathologies: Formulations and methods useful to treat ocular neovascularization (new blood vessel growth in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention there is provided a formulation suitable for the treatment of ocular neovascularization that may comprise flurbiprofen in a concentration and dose suitable for treating ocular...

20050261242 - Pharmaceutical compounds: r

20050261244 - Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity....

20050261245 - Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors: The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I. The above compounds...

20050261246 - Methods for treating inflammatory and autoimmune diseases: The present invention provides methods for treating inflammatory conditions, rheumatoid diseases, autoimmune conditions, and conditions associated with bone loss, comprising administering to a subject with an inflammatory condition an amount effective to treat the condition of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′ phosphate and pancratastatin-3′,4′...

20050261249 - Antisense composition and method for treating cancer: A method and composition for of treating cancer, and in particular, for arresting the progression of a solid or primary cancer to a more invasive, metastatic state, are disclosed. The composition includes a substantially uncharged antisense compound (i) having a nuclease-resistant backbone, (ii) capable of uptake by target cancer cells...

20050261247 - Inhibition of jun kinase: Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin...

20050261248 - New-4-pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives: This invention is directed to selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy....

20050261251 - Antiviral agents and methods of treating viral infections: The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compositions comprising these compounds....

20050261250 - Compositions and methods for inhibiting bone resorption: Disclosed are compositions and methods for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin D3 suitable for once-weekly dosing. Compositions and methods of the...

20050261252 - Lpa receptor agonists and antagonists and methods of use: The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA...

20050261253 - Kinase inhibitory phosphonate analogs: The invention is related to phosphorus substituted kinase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20050261254 - Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation: A method for inhibiting and/or ameliorating the occurrence of diseases in a human subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative. In some embodiments, the administration of analogs or derivatives of carotenoids may inhibit and/or ameliorate...

20050261255 - Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from...

20050261256 - Treatment of icu-associated hypocalcemia with vitamin d compounds: The present invention relates to a method of improving intensive care unit (ICU)-associated hypocalcemia in a mammal by the administration of a vitamin D compound, or other compounds exhibiting vitamin D-like activity, to the mammal for a sufficient period of time to improve or restore the serum calcium levels of...

20050261257 - Compositions for treating or preventing cardiovascular disease: Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular...

20050261258 - Methods and compositions for the non-surgical removal of fat: Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions...

20050261259 - Phytosterol and/or phytostanol derivatives: The present invention relates to a phytosterol and/or a phytostanol ester compound produced from the reaction of a phytosterol and/or a phytostanol with a polyunsaturated fatty acid (PUFA), wherein the polyunsaturated fatty acid has from 18 to 22 carbon atoms and at least three carbon-carbon double bonds. Processes for producing...

20050261260 - Combination of a cdk inhibitor and mitoxantrone: A first aspect of the invention relates to a combination comprising a CDK inhibitor and mitoxantrone. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and mitoxantrone as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the...

20050261261 - Eplerenone drug substance having high phase purity: A novel crystalline form (Form L) of the aldosterone receptor antagonist drug eplerenone is provided having relatively high physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form L eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a...

20050261263 - Benzoquinone ansamycins: The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer...

20050261262 - Rifamycin derivatives effective against drug-resistant microbes: Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently...

20050261264 - Rare-earth ternary complex: wherein M is a rare earth atom; n1 is 2 or 3; n2 is 2, 3, or 4; Rf1 and Rf2 are the same or different and are each a aliphatic group having 1 to 22 carbon atoms and containing no hydrogen atoms, an aromatic group containing no hydrogen atoms,...

20050261265 - Modulating cellular senescence by amphiphysin-1: The present invention relates to nucleic acid sequences and proteins involved in senescence and particularly, to nucleic acid sequences and proteins including amphiphysin and caveolin involved in cellular senescence and their use....

20050261266 - Radiopharmaceutical and methods of synthesis and use thereof: A novel group of apomorphine derivatives are provided that are well suited as radioimaging agents upon incorporation of radionuclides. Through reaction of D ring sites, the less reactive sites of the apomorphine A ring is modified in ways previously unattainable....

20050261267 - Pharmaceutical formulation: Pharmaceutical formulations comprising amoxycillin and clavulante in a ratio of from 10:1 to 20:1 are of use in the emperic treatment of infections potentially caused by DRSP....

20050261268 - Aminotriazole compounds useful as inhibitors of protein kinases: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders....

20050261269 - New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them: e

20050261270 - Modified beta-lactamases and uses thereof: A tool that can screen bacteria for β-lactamases against a panel of various antibiotics is desirable. A biosensor incorporating an indicator molecule into β-lactamases may achieve this purpose, but it requires that the attached indicator molecule must not impair the binding affinity of the protein to a great extent to...

20050261271 - Dipeptidyl peptidase inhibitors: t

20050261272 - Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase:

20050261273 - Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors: The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and condition associated with abnormal deposition of A-beta protein....

20050261274 - Lactams substituted by cyclic succinates as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of...

20050261275 - Therapeutic combination: This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including...

20050261276 - Novel sulphones for inhibition of gamma secretase: i

20050261277 - Pentacyclic oxepines and derivatives thereof, compositions and methods: The present invention provides a compound of the formula (I) wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC—OCO(C1-C6 alkyl), or —OSO2(C2-C6 alkyl); R0, R2 and R3 are each independently —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), —OSO2(C2-C6 alkyl)or halo; R4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or...

20050261278 - Selective serotonin receptor inverse agonists as therapeutics for disease: Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions....

20050261279 - Compounds: R7 represents hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; r independently represents an integer selected from 0, 1, and...

20050261280 - Stabilized antihistamine syrup: An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, such as a salt of ethylenediaminetetraacetic acid....

20050261281 - Pharmaceutical compounds: an ether group of formula —(CH2)—O—(CH2)v—R″ wherein v is equal to 1 or 2; R″ is as defined in the present application; a ketone group of formula —C(O)-Z′, wherein Z′ is as defined in the present application; a substituent having an hydroxyl function of formula —CH(OH)-Z′, Z′ being as defined...

20050261282 - Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines: The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy for pakinsonism....

20050261283 - Methods and compositions for the treatment of graft failure: The present invention provides methods and compositions for treating graft failure resulting from neointimal hyperplasia. These methods and compositions feature the use of platelet derived growth factor receptor (PDGFR) inhibitor compounds, such as N-phenyl-2-pyrimidine compounds (e.g., imatinib mesylate) to inhibit the biological activity of the PDGFR....

20050261284 - Diazinopyrimidines: e

20050261285 - Tetrahydropyran derivatives and their use as therapeutic agents: The present invention relates compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R15 and R16 represent a variety of substituents; and pharmaceutically acceptable salts thereof. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or...

20050261287 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors: e

20050261286 - Substituted cycloalkyl derivatives, process for the manufacture thereof and use thereof as medicament:

20050261288 - Tetracyclic lactam derivatives and uses thereof: The present invention relates to Tetracyclic Lactam Derivatives, compositions comprising an effective amount of a Tetracyclic Lactam Derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, an ischemic condition, renal failure, diabetes, a diabetic complication, a vascular disease, reoxygenation injury resulting from organ transplantation, Parkinson's disease,...

20050261289 - 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide: which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine,...

20050261290 - Novel compounds of proline and morpholine derivatives: wherein T is a (4 to 10)-membered heterocyclyl selected from the group consisting of and wherein R1, R2 and R3 are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formulas (I), (II), and (III) and methods of treating a condition that is...

20050261291 - 1,2-di(cyclic)substituted benzene compounds: e

20050261293 - Compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,...

20050261292 - Pharmaceutical composition containing n-sulfamoyl-n'-arylpiperazines for the treatment or inhibition of obesity and related conditions: s

20050261295 - Pyrimidine as plk inhibitors:

20050261294 - Substituted heteroaryl derivatives, compositions, and methods of use: The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor...

20050261296 - Indole, azaindole and related heterocyclic n-substituted piperazine derivatives: e

20050261297 - Nitrogen-containing heterocyclic compound: As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can...

20050261299 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors:

20050261300 - Liquid pharmaceutical formulations containing 3.7-diazabicyclo[3,3,1]nonane compounds and methods of treatment relating to arrhythmic events: A method of using 3,7-diazabicyclo[3,3,1]nonane compounds, preferably of 9,9-alkylene-3,7-diazabicyclo[3,3,1]nonane compounds, and most preferably to the use of tedisamil, and the physiologically acceptable acid addition salts and/or solvates thereof, in the form of a liquid pharmaceutical preparation for the treatment and/or inhibition of arrhythmic events in human patients, preferably in conversion...

20050261298 - Methods of treating conditions associated with an edg-7 receptor: In one aspect, the present invention provides a method for modulating an Edg-7 receptor mediated biological activity in a cell. A cell expressing the Edg-7 receptor is contacted with a modulator of the Edg-7 receptor which is capable of modulating an Edg-7 receptor mediated biological activity. In another aspect, the...

20050261301 - Therapeutic ion channel blocking agents and methods of use thereof: Various divalent ligands based on khellinone derivatives are described. These derivatives can be useful in the modulation of potassium channel activity in cells, including among others Kv1.3 channels found in T-cells. The compounds may also be useful in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis....

20050261302 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme and their therapeutic application: The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic...

20050261303 - N-phenyl-(2r,5s) dimethylpiperadine derivative: The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and...

20050261305 - Cyclic protein tyrosine kinase inhibitors: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders....

20050261304 - Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders: The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation....

20050261306 - Anti-neurodegenerative agents: The present invention provides methods for treating or preventing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), Huntington's disease, Parkinson's disease, Alzheimer's disease, dementia after cerebral vascular disorder, dementia accompanied by other neuronal degeneration. The present invention provides methods for treating or preventing neurodegenerative diseases comprising...

20050261307 - Inhibition of fgfr3 and treatment of multiple myeloma: Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having...

20050261308 - Quinolinone derivatives and uses thereof: t

20050261309 - Imidazole compounds: Imidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor expression, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions....

20050261310 - Piperazinylpiperidine derivatives as chemokine receptor antagonists: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as...

20050261311 - Piperizinones as modulators of chemokine receptor activity: e

20050261312 - Pharmaceutically acceptable inorganic and organic salts of 5-methylpyrazine-2-carboxylic acid-4-oxide: Methods for the preparation of pharmaceutically acceptable organic or inorganic salts of 5-methylpyrazinecarboxylic acid-4-oxide esters including tris(hydroxymethyl)aminomethanol, N,N-dimethylethanolamine, N-methyl-D-glucamine, L-Lysine, L-arginine, Na, K, Ca and Mg. The esters of 5-methylpyrazinecarboxylic acid-4-oxide are oxidized in aqueous hydrogen peroxide at a pH of 2.5 to 7 in the presence of a catalyst...

20050261313 - Substituted alkylamine derivatives and methods of use: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention...

20050261314 - 7-amino triazolopyrimidines for controlling harmful fungi: The invention relates to 7-amino triazolopyrimidines of formula (I), in which the substituents have the following meanings: R1, R2 represent hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl; or 5-membered or 6-membered heterocyclyl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom;...

20050261316 - A2b adenosine receptor antagonists: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea....

20050261315 - Amide derivatives as kinase modulators: The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of amide compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects....

20050261317 - Inhibitors of human phosphatidylinositol 3-kinase delta: Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3K5, while not significantly inhibiting activity of other PI3K...

20050261318 - Protein kinase inhibitors: Disclosed are compounds which inhibit or modulate the activity of protein kinases and pharmaceutical compositions containing such compounds. The disclosed compound contain two or more ligand moieties covalently linked together by one or more linking groups. Such compounds are useful for treating diseases or medical disorders mediated by protein kinases....

20050261319 - Novel 2-amino-4-quinazolinones and 2-amino-4-oxoquinazolones as lxr nuclear receptor binding compounds with partial agonistic properties: The present invention relates to compounds according to the general formulas (I) and/or (Ia), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds...

20050261320 - Compounds and methods for the treatment of cancer: (−)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (−)-OddC) or its derivative and its use to treat cancer in animals, including humans....

20050261322 - Hiv integrase inhibitors: Compounds of the present disclosure are spirocycle-substituted pyrimidinecarboxamides. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating HIV infection and AIDS....

20050261323 - Medical uses of novel carbamate-substituted pyrazolopyridine derivatives: wherein R1 is H or a di-C1-6-alkylaminocarbonyl radical, and R2 is a radical of the formula —O—C(X)—NR3R4 wherein X is O or S. The compound may also be administered in combination with at least one organic nitrate or NO donor, or in combination with at least one compound which inhibits...

20050261321 - Substituted organosulfur compounds and methods of using thereof: The present invention provides substituted di-, tri-, tetra- and penta-sulfide compounds and compositions, and methods of using the same for the treatment and/or prevention of a cell proliferative disorder. The present invention also provides methods for preparing trisulfide compounds and compositions....

20050261324 - Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4 and/or LPAM-1. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4 and/or LPAM-1. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia,...

20050261327 - 2-(bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation: Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway....

20050261325 - Gamma-aminoamide modulators of chemokine receptor activity: The present invention is directed to compounds of the formula (1), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor...

20050261326 - Metabolites of ecteinascidin 743: The purification and structure elucidation of several products of the metabolism of Et 743 by human cytochrome CYP3A4 have been accomplished. These compounds are abbreviated herein as “ETM” followed by a numeric value which represents the approximate molecular weight. Three compounds have been identified to date, namely ETM 305, ETM...

20050261328 - Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents: A pharmaceutical composition useful in the treatment of functional bladder disorders comprising an antimuscarinic agent and a beta-3-adrenoceptor agonist is described....

20050261329 - Opioid and opioid-like compounds and uses thereof: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage....

20050261330 - Derivatives of 2,2,4-trisubstituted tetrahydrofuran an antifungal agents: The present invention relates to derivatives of 2,2,4-trisubstituted tetrahydrofuran as potential antifungal agents. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing the fungal infections in mammals, preferably humans....

20050261331 - Substituted pyrrolopyridines: There are provided novel compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk....

20050261332 - Sulfonamides and uses thereof: e

20050261333 - Use of and some novel imidazopyridines: The use of compounds of formula (I) wherein R1, R3, R10, m and Ar are as defined in the Specification and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial is...

20050261334 - Bis-pyridino containing compounds for the use in the treatment of cns pathologies: N-n-Alkylation of nicotine converts nicotine from an agonist into an antagonist specifically for neuronal nicotinic acetylcholine receptor subtypes mediating nicotine-evoked dopamine release. Conformationally restricted analogs exhibit both high affinity and selectivity at this site, and are able to access the brain due to their ability to act as substrates for...

20050261335 - Carvedilol formulations: This invention relates to pharmaceutical formulations of carvedilol in which a solubilising agent is used to solubilise carvedilol in oils and/or lipids, and methods of of using these formulations to treat hypertension, congestive heart failure and angina....

20050261337 - Substituted quinoline derivatives: The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:...

20050261336 - Use of quinoline derivatives with anti-integrase effect and applications thereof: The invention relates to the use of 8-hydroxyquinoline 7-carboxylic acid derivatives in order to produce integrase-inhibiting medicaments, capable of blocking viral replication in the stages preceding integration, and if appropriate at the level of this integration stage, these medicaments being usable for the treatment of retroviral pathologies, in particular for...

20050261338 - Beta2-adrenergic receptor agonists: Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor....

20050261339 - Pyrazole compound and medicinal composition containing the same: V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR2, O, CO, S, SO or SO2) and so on; and Y designates a hydrogen atom,...

20050261343 - Anthranilamides and their use as pharmaceutical agents: Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described....

20050261342 - Metabolites of (+)-(2s,3s)-3(2-methoxy-5- trifluoromethoxybenzylamino)-2-phenyl-piperidine: Metabolites of (+)-(2S, 3S)-3-(2-methoxy-5-trifluoromethoxybenzylamino)-2-phenyl-piperidine, and use of same....

20050261341 - Novel processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol: The present invention provides various processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol. These processes may be characterized by the following scheme:...

20050261340 - Selective serotonin receptor inverse agonists as therapeutics for disease: Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions....

20050261344 - Treatment of lower urinary tract symptoms associated with overactive bladder in men and women: This invention relates to pharmaceutical combinations suitable for treating the lower urinary tract symptoms associated with either overactive bladder or mild to moderate benign prostatic hyperplasia, which combinations contain an alpha-adrenoceptor antagonist and a 5-HT4 antagonist. The combinations of the invention are particularly suitable for treating moderate or severe symptomatology....

20050261345 - 2,5-bis-diamine-'1,4! benzoquinone derivatives, for the treatment of alzheimer's disease a process for their preparation and intermediates therefor: 2,5-bis-diamine-[1,4]benzoquinonic derivatives, having a general formula (I) have proved useful for the treatment of Alzheimer's disease; a method for preparing them and intermediates used in said method are also described....

20050261346 - Benzamides and related inhibitors of factor xa: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders....

20050261347 - Dihydrobenzofuranyl alkanamine derivatives and methods for using same: v

20050261348 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor....

20050261349 - Medicine for prevention or treatment of diabetes: The present invention provides a medicine for preventing or treating a diabetes, which includes 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof, and glibenclamide as active ingredients. The present invention provides a method for preventing or treating a diabetes, which includes administering 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof,...

20050261350 - Pyrrolobenzimidazolones and their use as anti-proliferative agents: e

20050261352 - Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides:

20050261351 - Process for preparing ondansetron hydrochloride dihydrate having a defined particle size: The invention provides a process for preparing ondansetron hydrochloride dihydrate particles in which at least about 70% of the particles have a particle size of less than 250 μm, comprising the steps of: (a) preparing a solution comprising ondansetron hydrochloride and water; and (b) adding the solution into a precipitation...

20050261353 - Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents: that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of...

20050261354 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well...

20050261355 - Carvedilol hydobromide: The present invention relates to a salt of carvedilol, corresponding compositions containing such a carvedilol salt or corresponding solvates thereof, and/or methods of using the aforementioned compound(s) in the treatment of certain disease states in mammals, in particular man. The present invention further relates to a novel crystalline form of...

20050261356 - Methods and compositions for the treatment of chronic lymphocytic leukemia: The level of the leukemic lymphocytes in patients suffering from chronic lymphocytic leukemia (CLL) is reduced by the administration of certain indole or carbazole compounds, such as the nonsteroidal anti-inflammatory drug etodolac or related indole or carbazol compounds....

20050261357 - Indole derivatives and drugs containing the same: e

20050261358 - Cyclohexylurea compounds:

20050261361 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050261359 - Novel processes for preparing amorphous atorvastatin hemi-calcium: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050261360 - Novel processes for preparing amorphous atorvastatin hemi-calcium: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050261362 - Method of increasing endogenous adiponectin and leptin production: A formulation for and method of enhancing adiponectin and leptin secretion is disclosed. The method comprises contacting living cells with an inhibitor of the enzyme pyruvate dehydrogenase kinase (PDHK). The PDHK inhibitor causes the cells it contacts to increase adiponectin secretion as well as increasing the production of leptin. The...

20050261363 - Compounds isolated from gamboge resin having activity in inhibiting the growth of tumor/cancer cells and pharmaceutical compositions comprising the same: Disclosed herein are an acetone-extracted product obtained from gamboge resin and compounds further purified from said acetone-extracted product, including a new compound called formoxanthone A. The acetone-extracted product and the further purified compounds have been demonstrated to have activities in inhibiting the growth of tumor/cancer cells. Also disclosed are the...

20050261364 - Hexahydrofuro[2,3-b]furan-3-yl-n-{3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-benzyl-2-hydroxypropyl}carbamate as retroviral protease inhibitor: Compositions comprising bis-tetrahydrofuran benzodioxyolyl sulfonamide compounds that are surprisingly effective protease inhibitors and a second antiretroviral compound are disclosed. Methods of inhibiting retrovirus proteases, in particular multi-drug resistant retrovirus proteases, methods of treating or preventing infection or disease associated with retrovirus infection in a mammal, and methods of inhibiting viral...

20050261365 - Transthyretin stabilization: Dibenzofuran-4,6-dicarboxylic acid core structures having an aromatic substituent appended onto the at the C1 position using three different types of linkages are disclosed herein and shown to afford exceptional amyloidogenesis inhibitors that display increased affinity and greatly increased binding selectivity to TTR over all the other plasma proteins, relative to...

20050261367 - Methods for treating dermatological and other health-related conditions in a patient: A method is provided for treating a dermatological condition in a patient. The method includes (a) measuring the intracellular water content of the patient to provide an initial intracellular water content measurement; (b) administering to the patient at least one active agent; (c) re-measuring the intracellular water content of the...

20050261366 - Tri(alkylcarboxylato)gallium (iii) products and pharmaceutical compositions containing them: Provided are novel tri(alkylcarboxylato) gallium (III) compounds, exemplified by tripalmitato gallium (III), methods for making them, pharmaceutical compositions containing them, and methods of using the pharmaceutical compositions....

20050261368 - Preparation of levalbuterol hydrochloride: Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided....

20050261369 - Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor: This invention describes a new combination for the treatment of bladder function disorders which comprises a serotonin- and/or norepinephrine-reuptake inhibitor and a beta-3-adrenoceptor agonist....

20050261370 - Process for producing of an aminoalkylsulfonic acid and a method of salt exchange for a salt thereof: i

20050261371 - Pentanoic acid derivatives: wherein n is 0 or 1, R11 is hydrogen and chlorine, R5 is R7—CH2— or R8, or R5 and R11, taken together is alkylidene; R6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10, in which R9, R10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or...

20050261372 - Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid: The use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, nitrogen substituted by a (C1-C6)alkyl, (C3-C6)alkenyl, 3-oxo(C5-C6)alkyl, 3-oxo(C4-C6)alken-2-yl, phenyl(C1-C6)alkyl, phenyl(C2-C6)alkenyl, gem-diphenyl(C1-C6)alkyl, gem-diphenyl(C2-C6)alkenyl, (C1-C6)alcanoyl, optionally N-substituted alanyl, optionally N,N′-disubstituted lysinoyl, phenyl(C1-C6)alkylydene or gem-diphenyl(C1-C6)alkylidene group, and of the pharmaceutically acceptable salts thereof, for preparation of medicaments intended for the treatment of CNS diseases due to reduced...

20050261375 - Method for providing a cathartic effect: e

20050261374 - Process for the preparation of prostaglandins and analogues thereof: Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF2α....

20050261373 - Prostaglandin compounds for the treatment of obesity: Provided is a composition for treating obesity which comprises an effective amount of a prostaglandin compound, especially, a compound of formula (I)....

20050261376 -